We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of ...

Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...

Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax incentive from ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...

"I am thrilled to further strengthen and enrich Ocular's senior leadership team with the appointment of Namrata as Chief ...

Belite Bio will host a webcast on Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update. To join the webcast, please visit ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a ...

The Nippon India Large Cap Fund - Growth has an AUM of 34432.09 crores & has delivered CAGR of 19.91% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.57%.

ONL Therapeutics Inc. is a classic case of a University of Michigan spinout. The Ann Arbor biotechnology startup netted the largest VC deal in the state in Q3, closing an oversubscribed $65 million ...